256 related articles for article (PubMed ID: 33176814)
1. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
Jiang L; Liu J; Wei Q; Wang Y
Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
[TBL] [Abstract][Full Text] [Related]
2. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.
Machado I; López Guerrero JA; Navarro S; Mayordomo E; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2013 Jun; 462(6):665-71. PubMed ID: 23681112
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.
Gomez-Brouchet A; Mourcin F; Gourraud PA; Bouvier C; De Pinieux G; Le Guelec S; Brousset P; Delisle MB; Schiff C
Hum Pathol; 2010 Sep; 41(9):1220-30. PubMed ID: 20399482
[TBL] [Abstract][Full Text] [Related]
5. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
6. sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma.
Solooki S; Khozaei A; Shamsdin SA; Emami MJ; Khademolhosseini F
Iran J Immunol; 2013 Dec; 10(4):229-37. PubMed ID: 24375064
[TBL] [Abstract][Full Text] [Related]
7. Bayesian pretest probability estimation for primary malignant bone tumors based on the Surveillance, Epidemiology and End Results Program (SEER) database.
Benndorf M; Neubauer J; Langer M; Kotter E
Int J Comput Assist Radiol Surg; 2017 Mar; 12(3):485-491. PubMed ID: 27722873
[TBL] [Abstract][Full Text] [Related]
8. Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.
Devaney K; Vinh TN; Sweet DE
Hum Pathol; 1993 Nov; 24(11):1211-25. PubMed ID: 7503935
[TBL] [Abstract][Full Text] [Related]
9. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
10. The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach.
Park YK; Yang MH; Park HR
Skeletal Radiol; 1996 Jan; 25(1):13-7. PubMed ID: 8717113
[TBL] [Abstract][Full Text] [Related]
11. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
12. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
13. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
15. Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas.
Hasegawa T; Hirose T; Seki K; Hizawa K; Ishii S; Wakabayashi J
Cancer Detect Prev; 1997; 21(3):280-7. PubMed ID: 9167046
[TBL] [Abstract][Full Text] [Related]
16. Osteocalcin and Osteonectin Expression in Canine Osteosarcoma.
Wehrle-Martinez AS; Dittmer KE; Aberdein D; Thompson KG
Vet Pathol; 2016 Jul; 53(4):781-7. PubMed ID: 26926085
[TBL] [Abstract][Full Text] [Related]
17. FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb).
Al-Hassi HO; Ali NM; Cooke H; De Silva S; Brini AT; Babu P; Sumathi V; Morris MR; Niada S
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397231
[No Abstract] [Full Text] [Related]
18. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
19. Vimentin, osteocalcin and osteonectin expression in canine primary bone tumors: diagnostic and prognostic implications.
Amaral CB; Leite JDS; Fonseca ABM; Ferreira AMR
Mol Biol Rep; 2018 Oct; 45(5):1289-1296. PubMed ID: 30066297
[TBL] [Abstract][Full Text] [Related]
20. Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody.
Yoshikawa H; Rettig WJ; Takaoka K; Alderman E; Rup B; Rosen V; Wozney JM; Lane JM; Huvos AG; Garin-Chesa P
Cancer; 1994 Jan; 73(1):85-91. PubMed ID: 7506120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
